1. Pink Sheet
  2. >>Market Access
  3. >>PBMs

This Year, PBM-Directed Fury May Once Again Signify Nothing

 
• By Leslie Small

Anti-PBM sentiment continues to rise, but industry observers still question whether the reforms being discussed will be effective.

2025 Pink Sheet Perspectives
Industry observers questioned whether the PBM status quo will change, even if reform legislation is enacted. (Shutterstock)
Key Takeaways
  • Industry observers predicted that the risk of regulatory changes for PBMs will increase in 2025, but some were not sure reforms would be effective.

Federal legislators failed to act on the rising tide of anti-PBM sentiment in 2024, but health policy experts predict that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from PBMs

Orphan Drug Relief Still In Budget Bill But Uncertainty Remains

 
• By Cathy Kelly

The budget reconciliation bill nears final passage without pharmacy benefit manager reforms or provisions that would facilitate access to cell and gene therapies for children, but its Medicaid cuts pose a significant threat to prescription drug access.

Oz Says Big PBMs Have ‘Window’ to Quit Rebate System on Their Own

 
• By Leslie Small

CMS Administrator Mehmet Oz said PBMs may deserve "one last chance" to fix the rebate system before federal regulations and legislation are enacted.

PCMA, CVS, Cigna File Lawsuits Over ‘Dangerous’ Arkansas PBM Law

 
• By Tim Casey

The suits are an early test of the Arkansas law banning company ownership of PBMs and pharmacies in the state, as other states consider similar legislation.

PBM Investigation, Enforcement Action ‘Critical Priorities’ At FTC, Chair Says

 
• By Cathy Kelly

The new FTC chair addressed concerns that staffing cuts will undermine the commission’s commitment to pharmacy benefit manager oversight.

More from Pink Sheet Perspectives

US FDA’s Accelerated Approval Council: Bigger Role, More Transparency Coming?

 
• By Sue Sutter

The inspector general said the council should be more involved in specific approval decisions when there is internal disagreement, but FDA said that would preclude some individuals from adjudicating a subsequent withdrawal proceeding.

Confirmatory Trials: US FDA Expectations Become Clearer Amid FDORA Flexibilities

 
• By Sue Sutter

Two recent accelerated approval guidances describe the FDA’s policy expectations for trial timeliness, but recognize the need for case-specific determinations. Regulatory actions in 2024 show the FDA is willing to delay application filing or approval over confirmatory trial status.

Japan In 2025: Policy Give, Pricing Take Set To Continue

 
• By Lisa Takagi

While Japan looks set to further improve policies to support ventures and ease market entry this year, these will contrast with ongoing reimbursement price controls.